1 / 46

Il Polo senese ed il Distretto regionale scienze della vita nella prospettiva europea

Il Polo senese ed il Distretto regionale scienze della vita nella prospettiva europea. Dr. Francesco Maria Senatore Business Development Toscana Life Sciences Foundation. Argomenti. Polo Senese: TLS Distretto: Cluster Regionale Il mercato della Salute in Europa Le necessità delle imprese

dalit
Download Presentation

Il Polo senese ed il Distretto regionale scienze della vita nella prospettiva europea

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Il Polo senese ed il Distretto regionale scienze della vita nella prospettiva europea Dr. Francesco Maria Senatore Business Development Toscana Life SciencesFoundation TLS 2013

  2. Argomenti • Polo Senese: TLS • Distretto: Cluster Regionale • Il mercato della Salute in Europa • Le necessità delle imprese • Evoluzione del Cluster TLS 2013

  3. www.toscanalifesciences.org TLS 2013

  4. TLS Mission MPS Public Institutions University AppliedResearchResults Industrial Development Territory TLS 2013

  5. Siena - The Science Park • Monothematic : Life Sciences (Red Biotech) • drugs • diagnostics • medicaldevices • biomedicaltechnologies • Laboratories, offices, equipment and utilities • Consultingservices and support • Access to public and private financingtools JCVI April 2012

  6. Science Park Location: Siena - Novartis site Total surface area: 83.000 sq. mt. Total buildingssurface: 38.400 sq. mt. Labs (research/devel./Q.A.): 8.200 sq. mt. Production plants: 6.800 sq. mt. Warehouses: 2.800 sq. mt. Offices: 8.400 sq. mt. Services: 4.700 sq. mt. TLS bio-incubator • Industrial and academicresearchactivities • Center of excellencefor Novartis Vaccines • More than470 researchers • Common facilities, services and utilities JCVI April 2012

  7. TLS Bio-incubator • 10 laboratorymodules (rangingfrom 60 to 140 m2) fullyequippedaccordingto company’s needs • GMP facilityformedicinalproducts derived from human blood or plasma (160 m2) • Analyticallabs and common services (135 m2) • BSL 3 lab • Animal care facility • Offices, meeting rooms (600 m2) JCVI April 2012

  8. TLS - MainIncubationServices • Intellectualpropertyprotectionconsultancy • Technology Transfer/Start-upCreation • Business developmentcoaching • Grantssearch and applicationsupport • Scouting of industrial and financialpartners • Bio-partneringsupport • InfrastructureServices (Front office, meeting room, etc.) • Dedicatedscientificequipmentup to€ 200k • Common high-tech equipmentand facilities JCVI April 2012

  9. International CallforApplication Business Plansubmission Incubation Project selection TLS Executive Boardapproval Find Start up financing IncubationDeal-Flow: the ”Picking the WinnerApproach” JCVI April 2012

  10. TLS Evaluation Committee Dr. Andy Richards, Cambridge (UK) Dr. BertilSamuelsson, Stockholm (SE) Prof. Stephen Hanessian, Montréal (CA) Dr. Eva Pisa, Stockholm (SE) Dr. Elkan Gamzu, Boston (USA) JCVI April 2012

  11. Torre Fiorentina Campus – September2005 JCVI April 2012

  12. VisMederi srl Companies and ResearchGroups 2013 TLS 2013

  13. TLS Performance Indicators TLS 2013

  14. TLS IncubatedCompanies & ResearchGroups: Total Financial Resources JCVI April 2012

  15. TLS 2013

  16. Universities and ResearchCenters JCVI April 2012

  17. Tuscany-Health Care System Quality “33,9% of total clinicaltrialscarried out in Italy are performed in Tuscany” JCVI April 2012

  18. Some Big Players Head office : Calenzano (FI) Employees: 1.139 Turnover: € 211 Mil. Head office: Siena Employees: 2.400 Turnover: € 652 Mil. Head office : Florence Employees : 719 Turnover: € 214 Mil. Head office : Lucca Employees: 1.240 Turnover: € 240 Mil. Head office : Florence Employees : 3.000 in Tuscany, over 13.000 worldwide Turnover: € 3.004 Mil. Head office : Sesto Fiorentino (FI) Employees : 961 Turnover: € 628 Mil. TLS 2013

  19. Companies Italy Tuscany % Tuscany Biotech 221 30 14 Pharma 198 20 10 MedicalDevices 2.735 156 6 % Tuscany Turnover ( € Mil .) Italy Tuscany Biotech 7.157 1.630 23 Pharma 25.000 3.300 13 Medicaldevices 16.800 811 5 10.940 645 6 Tuscany is a strategic region in the Life Science PharmaServices TLS 2013

  20. TLS 2013

  21. National & internationalclusters The Tuscany Life Science Cluster Public Institutions Tuscany Life Sciences Cluster SteeringCommittee MemberRepresentativesCommittee Services Needs Entrepreneurial System TLS 2013

  22. EU Healthcare Market • Organisation for Economic Co-operation and Development (OECD) • www.oecd.org/ TLS 2013

  23. TLS 2013

  24. Growth in health spending per capita slowed or fell in real terms in 2010 in almost all European countries, reversing a trend of steady increases. • Spending had already started to fall in 2009 in countries hardest hit by the economic crisis but this was followed by deeper cuts in 2010 in response to growing budgetary pressures and rising debt-to-GDP ratios. • On average across the EU, health spending per capita increased by 4.6% per year in real terms between 2000 and 2009, followed by a fall of 0.6% in 2010. TLS 2013

  25. TLS 2013

  26. Reductions in public spending on health were achieved through a range of measures, including reductions in wages and/or employment levels, increasing direct payments by households for certain services and pharmaceuticals, and imposing severe budget constraints on hospitals. • Gains in efficiency have also been pursued through mergers of hospitals or accelerating the move from inpatient care to outpatient care and day surgery. TLS 2013

  27. The public sector is the main source of health care financing in all European countries. • In 2010, nearly three-quarter (73%) of all health spending was publicly financed on average in EU member states. • Public financing accounted for over 80% in the Netherlands, the Nordic countries (except Finland), Luxembourg, the TLS 2013

  28. Service supportto Life Science SME TLS 2013

  29. Internazionalizationis a challenge forSMEs TLS 2013

  30. SME’s supportneedforforeignmarkets • Alignyourproduct portfolio to the marketswith high growthpotential (market Analysis)• Develop market-entry and market-expansionstrategiesbyidentifying the regions and market segmentspoisedfor strong growth (StrategicPositioning)• Create a more tailoredcountrystrategythrough the understandingof market outlook and major trends (local link)• Develop key strategicinitiativesbyunderstanding the key focus areas and top-sellingproductsofleadingcompanies (match makingevents) TLS 2013

  31. Frameworkagreements withinstitutionalpartners Internationalization support Deepinsightinto companies’needs Network ofselected and qualifiedpartners

  32. NetworkingEurope’s Biocommunities TLS 2013

  33. ALISEI, Cluster nazionale Scienze della Vita “Advanced LIfeSciEnces in Italy”

  34. National Technology Cluster Call • The MIUR (Ministry of Education, Universities and Research) published a call for the creation of 9 National Technological Clusters corresponding to different high tech sectors, one of them is Life Science • For each sector only a single cluster has been created • Each Cluster presents 4 R&D projects • Total costs in between 10 and 12 millions of euro • A maximum of 8 proponents • Industrial partners covering at least the 50% of costs, with SME’s covering at least the 15% • Public partners covering at least the 35% of costs • The MIUR supports the call with 368 millions of euro, 63 millions as a contribution to the costs and 305 as subsidized credit. Moreover the MIUR allocates additional 40 millions of euro of contribution for projects involving Puglia, Calabria, Sicilia and Campania regions.

  35. Perchè un Cluster • Nuove dinamiche di sviluppo verso le economie basate sulla conoscenza e l’innovazione. Tra i fattori in grado di sostenere e promuovere la transizione vi sono le “reti di conoscenza”. • In linea con iniziative a livello europeo, come la Strategia di Lisbona e la “Europe 2020 Growth Strategy”, nella logica di un recupero di competitività grazie allo sviluppo di un’economia basata sulla conoscenza e sull’innovazione. • Una delle criticità che si intende superare con il Cluster è rappresentata dalla frammentazione delle iniziative nell’ambito Scienze della Vita: senza adeguata massa critica mancano effettive ricadute per l’intero sistema Paese. • L’ambizione è quella di favorire l’aggregazione di risorse non solo a livello regionale, ma anche tra i poli di riferimento nazionali e di entrare nelle grandi reti di aggregazione europee, partecipando ai “mega cluster” transnazionali che connettono i nodi specializzati esistenti in ciascun Paese (“Biotechnology strategy and action plan” della Commissione Europea )

  36. ALISEI - gli attori • ALISEI raccoglie strutture produttive e di ricerca, individuali e aggregate, appartenenti a 12 Regioni • In ALISEI sono rappresentate le Associazioni di categoria: Assobiomedica, Assobiotec, Farmindustriae vi partecipailsistemapubblicodellaricerca: CNR, ENEA, ICE, IIT • La governance di ALISEI è aperta, per accogliere ulteriori componenti scientifiche, industriali e istituzionali coerenti con la sua missione

  37. ALISEI: Cluster Strategicpositioning • Vision: Tobe a drivingforce in the economicgrowthofItalianregions in the fieldofhumanhealth • Mission: Toestablish a national network ofskills and capacitiesofresearch, innovation and industrial development in the Life Science sectorwith the aimofanswering the social and economicchallenges in the fieldofhumanhealth • Timeline: At least 5 years • Macrotrends: • Personalizedapproach and integrationbetweentherapy and diagnosis • Ageing and chronicdiseases • Convergenttechnologies

  38. The future International Level Mega Cluster EuropeanLevel National level Super Cluster Geographical Area Regionallevel Cluster Locallevel Science Park [++] [-] Virtual cluster integration [++] Relevanceofgeographicalproximity [-] Fonte: TLS elaborationfromSternberg(2003) TLS 2013

  39. Thankyou Francesco Maria Senatore Business Development Communication & Projects Tuscany Life Science Cluster & Foundation Via Fiorentina, 1 53100 Siena ITALY Tel.: +39 0577 231207 Mobile:+39 340 0917237 Fax: +39 0577 43444 f.senatore@toscanalifesciences.org www.toscanalifesciences.org TLS 2013

  40. Conclusions • International visibilityis key forR&D intensive and start-up companies • International presenceis key for mature/expansioncompanies • Bothtypesof SME can’t approach the market alone • Science Parks and Cluster organizations play a veryimportantrole in building up a realinternational network is key and should go beyond the EU TLS 2013

  41. National Cluster ranking 41

  42. TLS 2013

  43. Post-Incubation Building TLS 2013

  44. International Benchmarking TLS 2013

  45. Biotechclusters in US From V. Chiesa – Bioforum, Milano 2007 FM Senatore Bio-Europe

  46. Biotechclusters in EU From V. Chiesa – Bioforum, Milano 2007 FM Senatore Bio-Europe

More Related